UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/650/0.1/17.12.25 | Real-time BOERSE MUENCHEN 01:12:09 18/05/2024 am IST | ||
| 2.06 EUR | +8.99% |
|
| Current month | +94.34% | ||
| 1 month | +50.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 2.06 | +8.99% |
| 16/24/16 | 1.89 | +1.61% |
| 15/24/15 | 1.86 | +14.11% |
| 14/24/14 | 1.63 | -4.68% |
| 13/24/13 | 1.71 | +13.25% |
Real-time BOERSE MUENCHEN
Last update May 18, 2024 at 01:12 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD1UUP |
| ISIN | DE000HD1UUP9 |
| Date issued | 15/01/2024 |
| Strike | 650 $ |
| Maturity | 17/12/2025 (577 Days) |
| Parity | 10 : 1 |
| Emission price | 2.85 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.37 € |
|---|---|
| Lowest since issue | 1.02 € |
| Spread | 0.03 € |
| Spread % | 1.44% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Warrants
- Warrant
